Search results
Found 560 matches for
Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.
Let’s just get married – the story of an acquisition
5 March 2026
"We decided to skip the engagement and just get married" – that’s how Hutano Diagnostics’ CEO Atherton Mutombwera describes his company’s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser’s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.
Theolytics awarded €8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer
4 March 2026
Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.
Infinitopes: Preventing Cancer Recurrence
3 March 2026
Infinitopes has been featured in a recent blog post by Amplify, highlighting their work to prevent cancer recurrence and their approach to advancing precision immunotherapies.
U-Ploid Biotechnologies launches collaborative research study with San Diego Fertility Center and Nova Genomics
24 February 2026
U-Ploid Biotechnologies has initiated a new collaborative research study with San Diego Fertility Center (SDFC) and Nova Genomics, marking an important translational step in the company’s programme to address the biological causes of age-related infertility.
BiotechTV talks to clinical-stage tenant Infinitopes on its second BioEscalator visit
20 February 2026
On its recent visit to Oxford, leading biotech sector commentator Biotech TV had a fascinating and wide-ranging conversation with Dr Jonathan Kwok, the CEO of BioEscalator tenant Infinitopes.
Highlighting our award-winning apprentices in NAW 2026
16 February 2026
Apprentices are a vital part of BioEscalator life, and we always enjoy celebrating their achievements and impact in National Apprenticeship Week.
Nucleome Therapeutics appoints experienced biotech executive Dr Michelle Morrow as Chief Scientific Officer
16 February 2026
Dr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment reflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.
U-Ploid Biotechnologies appoints Tim Stonehouse as Head of Regulatory Affairs
10 February 2026
U-Ploid Biotechnologies (U-Ploid), an Oxford-based biotechnology company pioneering first-in-class therapeutics for reproductive health, today announced the appointment of Tim Stonehouse as the company’s first in-house Head of Regulatory Affairs.
AstraZeneca Exchange launches in Oxford with support for BioEscalator tenants
3 February 2026
What started out as an initiative to embed AstraZeneca into Cambridge's ecosystem has turned into a Science and Business Mentoring programme, AstraZeneca Exchange, which has now been launched at the University of Oxford. So far four BioEscalator tenants who will benefit from this valuable scheme have been named - Infinitopes, Spectre Bio, Granza Bio and ISOgenix Limited.
OMass Therapeutics appoints Jonathan Montagu as Chair of the Board of Directors
28 January 2026
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announced updates to its Board of Directors, including the appointment of Jonathan Montagu, Chief Executive Officer and co-founder of HotSpot Therapeutics, as Board Chair.
First Cambridge – Oxford BioVenture Showcase proves a success
22 January 2026
The positive feedback from investors and presenting companies at our recent first Cambridge – Oxford BioVenture Showcase with the Milner Therapeutics Institute shows what a success it was. We will certainly be doing it again!
Infinitopes expands seed financing to $35 Million to accelerate clinical development of precision cancer vaccine
21 January 2026
Financing co-led by Octopus Ventures and new investor Amplify Bio. Company readies its first-in-human clinical trial of ITOP1, a precision cancer vaccine designed to prevent recurrence in oesophageal cancer.
Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies
8 January 2026
Boehringer Ingelheim has licensed additional Dark Antigens from various tumour types, enhancing Enara’s eligibility for milestone payments under their collaboration. Scott Drutman, M.D., Ph.D. has been appointed as Chief Medical Officer, bringing valuable expertise in translational medicine and immuno-oncology. Enara’s ENA101, a bispecific T-cell engager targeting the DARKFOX antigen, is planned to enter First-in-Human studies in 2026, while the company continues expanding its EDAPT discovery platform to include cell-surface Dark Antigens.
U-Ploid Biotechnologies to present five scientific abstracts at Fertility 2026
8 January 2026
U-Ploid Biotechnologies, a biotechnology company developing next-generation reproductive therapeutics to address age-related fertility decline, today announced that five scientific abstracts have been accepted for presentation at Fertility 2026 in Edinburgh. The presentations take place today, 8 January 2026.
Certis Belchim and Moa sign strategic collaboration deal
8 January 2026
Netherlands-based company becomes Moa's third major commercial partner in 18 months.
Nucleome Therapeutics nominates first preclinical development candidate
7 January 2026
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.
Oxford Cancer Analytics graduates from the BioEscalator
15 December 2025
In 2022, Oxford Cancer Analytics was voted the company Most Likely to be a Unicorn at that year’s BioEscalator Pitch Battle. Fast forward three years, and the company is well along its growth trajectory. OXcan has graduated from our facility as a fast-scaling diagnostics company, leveraging advanced proteomics and machine learning to develop innovative tests for earlier and more accurate assessment of lung diseases.
BioEscalator Annual Review 2024/25 - People and partnerships driving better patient health
11 December 2025
In 2024/25, the BioEscalator community achieved remarkable milestones through collaboration with individuals and organisations across the innovation ecosystem. Our annual review, titled "People and partnerships driving better patient health," highlights significant accomplishments and companies such as Oxford Cancer Analytics, with its global perspective. Working with the University of Oxford, alongside tenants and alumni, has been significant in advancing the bioscience industry. This year emphasises our commitment to embracing new ideas while making a meaningful impact.
BioEscalator Bulletin - Winter 2025
11 December 2025
Stay informed with the latest BioEscalator updates, tenant and alumni news in the Winter 2025 edition of the BioEscalator Bulletin.
Akimbo Bio crosses the bridge from academia to industry as it joins the BioEscalator
3 December 2025
The BioEscalator is pleased to welcome Akimbo Bio to its community of innovative bioscience start-ups. Co-founded by two Oxford researchers, the company is developing a next-generation immunotherapy platform that leverages intelligent receptor crosstalk to enhance both the efficacy and safety of cancer treatments.